Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06234137
Other study ID # KY2021-113
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 27, 2021
Est. completion date August 1, 2031

Study information

Verified date January 2024
Source First Affiliated Hospital of Wenzhou Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, open, multi-center, single arm trial. The treatment group will receive six cycles of docetaxel, carboplatin combined with Inetetamab and Pyrotinib before surgery. By focusing on tpCR (ypT0/is, ypN0) evaluated by pathology, the efficacy of docetaxel, carboplatin combined with Inetetamab and Pyrotinib in the preoperative treatment of locally advanced HER2-positive breast cancer will be evaluated. During long-term follow-up, event-free survival (EFS), disease-free survival (DFS), distant metastasis-free survival (DDFS), overall survival (OS), central nervous system disease-free survival (CNSDFS) under this treatment regimen will be evaluated, and the efficacy-related biomarkers will be explored. The cardiotoxicity of Inetetamab and Pyrotinib in the treatment of breast cancer is also be evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 154
Est. completion date August 1, 2031
Est. primary completion date July 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Female patients aged 18-75 years old; 2. ECOG score 0-1; 3. Breast cancer meets the following criteria: Histologically confirmed invasive breast cancer, primary tumor diameter > 2 cm as determined by standard evaluation methods at the research center; tumor stage: locally advanced; 4. HER2 expression-positive breast cancer confirmed by pathological examination; 5. Known hormone receptor status (ER and PR); 6. The functional level of major organs must meet the following requirements (no blood transfusion within 2 weeks before screening, no use of white blood cell and platelet-raising drugs): (1) Blood routine: neutrophil (ANC) >= 1.5×10^9/L; platelet count (PLT) >= 90×10^9/L; hemoglobin (Hb) >= 90 g/L; (2) Blood biochemistry: total bilirubin (TBIL) <= upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 1.5×ULN; alkaline phosphatase <= 2.5×ULN; urea nitrogen (BUN) and creatinine (Cr) <= 1.5×ULN; (3) Echocardiography: left ventricular ejection fraction (LVEF) >= 60%; (4) 12-lead ECG: Fridericia-corrected QT interval (QTcF) < 470 msec; 7. Female patients who are not menopausal or surgically sterilized: agree to abstain from sex or use effective contraceptive methods during treatment and for at least 7 months after the last dose in the study treatment; 8. Voluntarily join the study, sign the informed consent, have good compliance and are willing to cooperate with follow-up. Exclusion Criteria: 1. IV (metastatic) breast cancer; 2. Received anti-tumor therapy or radiotherapy for any malignant tumor in the past, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma and other malignant tumors; 3. Receiving anti-tumor therapy in other clinical trials at the same time, including endocrine therapy, bisphosphonate therapy or immunotherapy; 4. Received major surgical operations unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical operations; 5. Severe cardiac disease or discomfort, including but not limited to the following: a history of heart failure or systolic dysfunction (LVEF < 60%); high-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate > 100 bpm , significant ventricular arrhythmia (eg, ventricular tachycardia) or higher-grade AV block (ie, Mobitz II second-degree AV block or third-degree AV block); antianginal medication indicated angina pectoris; clinically significant heart valve disease; transmural myocardial infarction on ECG; poorly controlled hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg); 6. Inability to swallow, intestinal obstruction, or other factors that affect drug taking and absorption; 7. Those who are known to have a history of allergy to the drug components of this regimen; have a history of immunodeficiency, including HIV positive test, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation; 8. Female patients during pregnancy and lactation, female patients with fertility and positive baseline pregnancy test, or patients of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study drug; 9. Have serious comorbidities or other comorbidities that would interfere with planned treatment, or any other condition that the investigator considers the patient unsuitable to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Docetaxel
75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
Carboplatin
AUC=6 min/mL iv 3-weekly
Inetetamab
8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
Pyrotinib
400mg orally daily

Locations

Country Name City State
China the First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Wang Ouchen

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary tpCR total pathological complete response Approximately 5 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 6)
Secondary EFS Event-free survival Randomization up to a maximum of 329 weeks
Secondary DFS Disease-free survival Randomization up to a maximum of 329 weeks
Secondary DDFS Distant disease free survival Randomization up to a maximum of 329 weeks
Secondary OS Overall survival Up to 2 years
Secondary CNS-DFS Central nervous system disease-free survival Randomization up to a maximum of 329 weeks
See also
  Status Clinical Trial Phase
Completed NCT03980626 - Study on Physical Activity's Relationship With Cancer and Cognition N/A
Completed NCT04329819 - Satisfaction and QUality of Life After Breast REconstruction
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Active, not recruiting NCT03900884 - Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer Phase 1
Completed NCT05042999 - The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures N/A
Not yet recruiting NCT03662633 - Diagnosis Value of SEMA4C in Breast Cancer
Recruiting NCT05075512 - The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer Phase 2
Recruiting NCT04456855 - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Not yet recruiting NCT03629509 - BEFORE Decision Aid Implementation Study N/A
Completed NCT04811378 - HaemoCerTM Application in Breast Cancer Surgery N/A
Completed NCT03198442 - Breast PET Feasibility N/A
Not yet recruiting NCT05577442 - Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer Phase 2
Enrolling by invitation NCT04047823 - Temperature and Injury in Radiotherapy Radiation Skin Injury
Recruiting NCT05452213 - Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients Phase 4
Recruiting NCT05027321 - Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies N/A
Active, not recruiting NCT04812652 - Digitally Distributed Yoga for Women Treated for Breast Cancer N/A
Active, not recruiting NCT03425838 - Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer Phase 3
Completed NCT05473026 - Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors N/A
Completed NCT04509063 - Investigating Public Enthusiasm for Mammography Screening in Denmark N/A
Recruiting NCT05711030 - Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery N/A